Clinical Trials

Neoplasms, Colorectal Neoplasms

NCT06447662 2026-02-25

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

330 enrolled

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT05647122 2026-02-20

EGRET

GastrointestinalHead & NeckThoracic

403 enrolled

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Neoplasms, Colorectal Neoplasms

NCT04449874 2026-02-12

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Phase 1 Active not recruiting

498 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

NCT07323576 2026-02-09

INAVO-CRC

Phase 2 Withdrawn

Phase 1/2 Not yet recruiting

Colorectal Neoplasms

NCT07391566 2026-02-06

LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

99 enrolled

Colorectal Neoplasms

NCT05733611 2026-02-02

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Phase 2 Terminated

5 enrolled

Phase 3 Active not recruiting

Colorectal Neoplasms

NCT04854668 2026-01-30

A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

748 enrolled

Colorectal Neoplasms

NCT07222800 2026-01-30

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Phase 3 Recruiting

800 enrolled

GastrointestinalGenitourinary

Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Rectal Diseases, Colorectal Neoplasms

NCT03798626 2026-01-27

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Phase 1 Completed

167 enrolled

Carcinoma, Renal Cell, Colorectal Neoplasms

NCT06948448 2026-01-21

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

Phase 2 Recruiting

144 enrolled

Colorectal Neoplasms

NCT06792695 2026-01-20

CANTOR

Phase 2 Recruiting

120 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT06400472 2026-01-14

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

BreastGastrointestinalGynecologicThoracic

495 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06106308 2026-01-12

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Phase 2 Active not recruiting

113 enrolled

Colorectal Neoplasms

NCT07277270 2026-01-07

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

84 enrolled

Neoplasms, Colorectal Neoplasms

NCT07318805 2026-01-06

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

260 enrolled

BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT06730750 2025-12-15

A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

Phase 1/2 Recruiting

360 enrolled

Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Colorectal Neoplasms

NCT07244705 2025-11-24

A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

Phase 1/2 Recruiting

66 enrolled

Phase 2/3 Active not recruiting

Disease, Colorectal Neoplasms

NCT05945901 2025-11-18

A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer

669 enrolled

Colorectal Neoplasms

NCT05839951 2025-11-12

STAR-T

Completed

818 enrolled

Phase 1 Active not recruiting

Colonic Neoplasms, Colorectal Neoplasms

NCT05029882 2025-10-29

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

520 enrolled

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT04660812 2025-10-20

ARC-9

Phase 1/2 Completed

227 enrolled

Phase 3 Active not recruiting

Colorectal Neoplasms

NCT04008030 2025-10-03

CheckMate 8HW

839 enrolled 22 charts 1 FDA

Phase 1/2 Active not recruiting

Colorectal Neoplasms

NCT05609370 2025-10-02

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

113 enrolled

Colorectal Neoplasms

NCT03929666 2025-09-12

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Phase 2 Completed

74 enrolled

Biliary Tract Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT06614192 2025-08-26

A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

Phase 3 Recruiting

460 enrolled

Phase 3 Active not recruiting

Colorectal Neoplasms

NCT04607421 2025-08-14

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

831 enrolled 2 FDA

Phase 1 Active not recruiting

Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms

NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

138 enrolled

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT05480306 2025-08-03

DeFianCe

Phase 2 Completed

188 enrolled

GastrointestinalGynecologic

Colonic Neoplasms, Colorectal Neoplasms

NCT05489211 2025-07-11

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Phase 2 Recruiting

582 enrolled

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05330429 2025-07-01

ELEVATE CRC

Phase 2 Terminated

77 enrolled 22 charts

Phase 3 Not yet recruiting

Colorectal Neoplasms

NCT07025239 2025-06-17

QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer

430 enrolled

Phase 2/3 Active not recruiting

Colorectal Neoplasms

NCT05141721 2025-05-16

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

700 enrolled